Rapport Therapeutics Common Stock Market Value
| RAPP Stock | 26.93 0.49 1.85% |
| Symbol | Rapport |
Can Pharmaceuticals industry sustain growth momentum? Does Rapport have expansion opportunities? Factors like these will boost the valuation of Rapport Therapeutics. Anticipated expansion of Rapport directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Rapport Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Rapport Therapeutics is measured differently than its book value, which is the value of Rapport that is recorded on the company's balance sheet. Investors also form their own opinion of Rapport Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rapport Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Rapport Therapeutics' market value can be influenced by many factors that don't directly affect Rapport Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rapport Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rapport Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rapport Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Rapport Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rapport Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rapport Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Rapport Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Rapport Therapeutics Common or generate 0.0% return on investment in Rapport Therapeutics over 90 days. Rapport Therapeutics is related to or competes with Nurix Therapeutics, Kodiak Sciences, Phathom Pharmaceuticals, Xencor, BridgeBio Oncology, AnaptysBio, and UroGen Pharma. Rapport Therapeutics is entity of United States More
Rapport Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rapport Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rapport Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.86 | |||
| Information Ratio | 0.0023 | |||
| Maximum Drawdown | 16.72 | |||
| Value At Risk | (6.76) | |||
| Potential Upside | 6.16 |
Rapport Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rapport Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rapport Therapeutics' standard deviation. In reality, there are many statistical measures that can use Rapport Therapeutics historical prices to predict the future Rapport Therapeutics' volatility.| Risk Adjusted Performance | 0.0244 | |||
| Jensen Alpha | 0.0466 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | 0.0022 | |||
| Treynor Ratio | 0.1781 |
Rapport Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0244 | |||
| Market Risk Adjusted Performance | 0.1881 | |||
| Mean Deviation | 2.96 | |||
| Semi Deviation | 3.72 | |||
| Downside Deviation | 3.86 | |||
| Coefficient Of Variation | 4495.37 | |||
| Standard Deviation | 3.75 | |||
| Variance | 14.04 | |||
| Information Ratio | 0.0023 | |||
| Jensen Alpha | 0.0466 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | 0.0022 | |||
| Treynor Ratio | 0.1781 | |||
| Maximum Drawdown | 16.72 | |||
| Value At Risk | (6.76) | |||
| Potential Upside | 6.16 | |||
| Downside Variance | 14.87 | |||
| Semi Variance | 13.82 | |||
| Expected Short fall | (2.88) | |||
| Skewness | 0.1404 | |||
| Kurtosis | (0.06) |
Rapport Therapeutics Backtested Returns
Rapport Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.0253, which implies the firm had a -0.0253 % return per unit of risk over the last 3 months. Rapport Therapeutics exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Rapport Therapeutics' Risk Adjusted Performance of 0.0244, coefficient of variation of 4495.37, and Semi Deviation of 3.72 to confirm the risk estimate we provide. The company holds a Beta of 0.41, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Rapport Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Rapport Therapeutics is expected to be smaller as well. At this point, Rapport Therapeutics has a negative expected return of -0.0889%. Please make sure to check Rapport Therapeutics' skewness, and the relationship between the value at risk and day median price , to decide if Rapport Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.76 |
Almost perfect reverse predictability
Rapport Therapeutics Common has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Rapport Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rapport Therapeutics price movement. The serial correlation of -0.76 indicates that around 76.0% of current Rapport Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.76 | |
| Spearman Rank Test | -0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 2.92 |
Pair Trading with Rapport Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Rapport Stock
| 0.41 | 300363 | Porton Fine Chemicals | PairCorr |
| 0.36 | JAGX | Jaguar Animal Health | PairCorr |
| 0.34 | SNY | Sanofi ADR Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Rapport Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics Common to buy it.
The correlation of Rapport Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.